Dr. Basu on Second-Line Therapy in HCC

Bristi Basu, MD
Published: Thursday, Sep 27, 2018



Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discusses second-line therapy for hepatocellular carcinoma (HCC).

Researchers had not seen efficacy with any agents in the second-line setting until the RESOURCE trial. This was a phase III study with 2:1 randomization of regorafenib (Stivarga) versus sorafenib (Nexavar). These are 2 very similar tyrosine kinase inhibitors with slightly different mechanisms of action. This slight distinction allows regorafenib to have activity against VEGF-2 and FGF1. Data showed a survival advantage for regorafenib compared with placebo, 10.6 months versus 7.8 months, respectively. Response rates were modest, about 11%.

Basu adds that this was a patient population with a generally good prognosis. They were able to tolerate sorafenib at a dose of 400 mg/day for 20 days, but progressed on the treatment. There were similar adverse events with regorafenib as are seen in patients treated with sorafenib.


Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discusses second-line therapy for hepatocellular carcinoma (HCC).

Researchers had not seen efficacy with any agents in the second-line setting until the RESOURCE trial. This was a phase III study with 2:1 randomization of regorafenib (Stivarga) versus sorafenib (Nexavar). These are 2 very similar tyrosine kinase inhibitors with slightly different mechanisms of action. This slight distinction allows regorafenib to have activity against VEGF-2 and FGF1. Data showed a survival advantage for regorafenib compared with placebo, 10.6 months versus 7.8 months, respectively. Response rates were modest, about 11%.

Basu adds that this was a patient population with a generally good prognosis. They were able to tolerate sorafenib at a dose of 400 mg/day for 20 days, but progressed on the treatment. There were similar adverse events with regorafenib as are seen in patients treated with sorafenib.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x